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Abstract
Background: This study investigated the costs and outcomes of implementing cognitive behavior
therapy (CBT) for chronic fatigue syndrome (CFS) in a mental health center (MHC). CBT is an
evidence-based treatment for CFS that was scarcely available until now. To investigate the
possibilities for wider implementation, a pilot implementation project was set up.
Method: Costs and effects were evaluated in a non-controlled before- and after study with an
eight months time-horizon. Both the costs of performing the treatments and the costs of
implementing the treatment program were included in the analysis. The implementation
interventions included: informing general practitioners (GPs) and CFS patients, training therapists,
and instructing the MHC employees. Given the non-controlled design, cost outcome ratios (CORs)
and their acceptability curves were analyzed. Analyses were done from a health care perspective
and from a societal perspective. Bootstrap analyses were performed to estimate the uncertainty
around the cost and outcome results.
Results: 125 CFS patients were included in the study. After treatment 37% had recovered from
CFS and the mean gained QALY was 0.03. Costs of patients' health care and productivity losses
had decreased significantly. From the societal perspective the implementation led to cost savings
and to higher health states for patients, indicating dominancy. From the health care perspective the
implementation revealed overall costs of €5.320 per recovered patient, with an acceptability curve
showing a 100% probability for a positive COR at a willingness to pay threshold of €6.500 per
recovered patient.
Conclusion: Implementing CBT for CFS in a MHC appeared to have a favorable cost outcome
ratio (COR) from a societal perspective. From a health care perspective the COR depended on
how much a recovered CFS patient is being valued. The strength of the evidence was limited by the
non-controlled design. The outcomes of this study might facilitate health care providers when
confronted with the decision whether or not to adopt CBT for CFS in their institution.
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Background
Chronic Fatigue Syndrome (CFS) is characterized by per-
sistent or relapsing unexplained fatigue that lasts for at
least six months and results in substantial reduction in
previous levels of daily functioning [1]. Causes of CFS
have not been found and most patients do not recover
spontaneously [2]. Based on the CDC-94 criteria, CFS
prevalence figures of 112 and 420 per 100.000 were found
[3,4].
Cognitive behavior therapy (CBT) has proven to be an
effective treatment for CFS [5,6]. Since the treatment of
CFS with CBT has been available only in a few specialized
university medical centers in The Netherlands, just a small
minority of CFS patients can benefit from it. Nationwide
implementation is needed to realize access to CBT treat-
ment for all CFS patients. However, when decision makers
have to judge whether such implementation is worth-
while and should be paid for, they need information
about its costs and benefits for individual patients, the
healthcare system and society.
The number of cost effectiveness analyses (CEA) of CBT
for CFS and chronic fatigue (CF) are few compared to clin-
ical evaluations. One study performed a cost consequence
analysis of CBT for CF in general practice compared to reg-
ular counseling by a GP. It reported that counselling was
a less costly intervention than CBT, and that both inter-
ventions led to reductions in fatigue. But no overall cost-
effectiveness advantage was found for either form of ther-
apy [7]. Another study, concerning a CEA of CBT for CF,
[8] found similar cost effectiveness for CBT and graded
exercise for CF. It also reported a high probability that
these therapies are cost-effective compared to usual care.
A third study reported a CEA of CBT for CFS and found,
although with some statistical uncertainties, that regard-
ing a time horizon of 14 months, total costs to society
were lower for (ex) CFS patients that had followed CBT
treatment than for those who had received usual care or
guided support groups [9]. Taken together these studies
indicate that CBT for CFS or CF might be cost effective for
society compared to usual care.
Until now nothing is known about the costs and effi-
ciency of implementing CBT for CFS in a clinical practice
setting. It might be possible that the efficiency of CBT for
CFS reduces if the implementation costs are high or if the
treatment effectiveness reduces. The present study there-
fore evaluated the broader so-called policy costs and effects
of a pilot implementation project in which CBT for CFS
was made available in a mental health center (MHC). In a
policy study all extra costs of implementing the treatment
(like training therapists, informing GPs, organizing and
meetings) are being included as fixed costs in the analysis,
in addition to the costs and effects of just performing the
treatment [10,11].
The MHC of this study was a regional middle-sized insti-
tution located in the East of The Netherlands, covering
mostly rural and some urbanized areas. It had locations in
four separate sub-regions and the CBT for CFS treatment
was offered at two of them. This MHC was the main pro-
vider of mental health care in this area, offering outpatient




The evaluation was a prospective, non-controlled before
and after comparison in a MHC with an observation
period of 8 months.
Implementation interventions
The implementation program contained four major inter-
ventions. First, six behavior therapists who were working
in the concerning MHC were trained at the Nijmegen
Expertcenter for Chronic Fatigue. They were selected on
bases of their prior education in CBT and on their willing-
ness and possibility to participate in this implementation
project. None of these therapists had previous experience
with CFS patients. Their number of years working as a
behavioral therapist varied from two to 13 years. Second,
because GPs in the region were not familiar with this new
treatment setting for CFS, announcements were made in
the media and information brochures were distributed to
GPs. GPs could also order copies of these brochures for
their waiting rooms. Third, informational interventions
were performed that were directed at the patient popula-
tion. These consisted of several media announcements
and distribution of patient brochures. Fourth, employees
of the mental health care institution were informed and,
if applicable, settled into the project.
Patients and treatment procedure
Patients who attended the treatment were all diagnosed as
CFS and referred to the MHC by their GP or a medical spe-
cialist. Inclusion criteria were as follows: a GPs diagnosis
of CFS (based on the CDC-94 criteria), not enrolled in a
new claim for disability-related benefits, and 18 years or
older. After the first session the patient had to fill in sev-
eral fatigue related paper and pencil questionnaires. At 8
months follow up, when treatment was finished, the
questionnaire had to be filled in again. Before starting this
study it was judged by the Nijmegen Medical Hospital
Ethical Commission, who indicated no need for informed
consent.
To measure fatigue we used the Checklist Individual
Strength (CIS20), which is a self-report measure on a 7-
point Likert scale for fatigue severity over the last two
weeks. The CIS has good reliability (Cronbach's alpha var-
ying from 0,83 to 0,92) and discriminative validity [12].
Physical functioning in daily life was measured with theBMC Health Services Research 2008, 8:175 http://www.biomedcentral.com/1472-6963/8/175
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'physical functioning' subscale of the SF-36 [13]. This sub-
scale is a validated 10-item scale with a score varying from
0 (maximum of limitations) to 100 (no limitations). The
Euroqol-5d was used to measure QALYs [14].
In some instances this questionnaire results contradicted
the diagnosis of CFS. For example, when a psychiatric co-
morbidity was found that could explain the severe fatigue.
In such occasions treatment was not started and the
patient was referred to another treatment program in the
organization.
The CBT treatment protocol prescribes 16 sessions in a
period of 8 months [15]. In this treatment, first the model
of psychological and behavioral perpetuating factors of
fatigue is explained to the patient. Then the patient formu-
lates his or her goals for therapy. Afterwards the patient
starts a structured graded activity program beginning with
some daily minutes of walking or bicycling, which is tai-
lored to their base line daily activity level. Subsequently,
dysfunctional fatigue related cognitions are being chal-
lenged to diminish somatic attributions of fatigue, to
improve a sense of control over symptoms and to facili-
tate behavior change. Finally a plan for work rehabilita-
tion is outlined and worked out. Patients without a paid
job focus on rehabilitation in other personal activities.
The last session deals with relapse prevention and further
improvement of self-control.
Measurement and valuation
1. Treatment implementation costs
Personnel costs, for therapists' trainings, coordinating
activities and monthly working group assemblies, were
calculated by counting the total amount of hours that con-
cerned people had invested and by multiplying these
hours with personnel's gross salary per hour, including
39% employers' charges. For training and supervision
only the hours that were actually attended were calcu-
lated, per person. The hours that people had spent on the
implementation were counted retrospectively by inter-
viewing concerned people. Traveling costs related to these
activities were calculated by summing up the total
amount of kilometers by car and counting  0.16 per kil-
ometer. Material costs for informing GPs and patients
were determined by summing up al printing, copying and
distributing costs of used materials. Accommodation
costs were calculated as 10% of personnel costs [16].
2. CBT integral treatment costs
For the CBT for CFS treatments integral prices were calcu-
lated, implying that all direct (executing) and indirect
(overhead) costs of the MHC for offering the treatment
were included in the calculation. Total costs of performed
treatment sessions were determined by first summing up
all therapists, diagnostic assistants and secretaries invested
time per treatment. For each patient the total number of
attended therapy sessions was registered. Planned ses-
sions that were cancelled less than 24 hours before the ses-
sion were also calculated. Per session one hour of work
was counted for a therapist. Per treated patient 15 minutes
secretary work was counted. Per intake and per post treat-
ment session 30 minutes work for a diagnostic assistant
was counted. The personnel costs for secretaries and diag-
nostic assistants were also based on gross salary plus39%
charges. Then, for overhead costs and building use, 20%
and 10% respectively of personnel costs were added to the
personnel costs [16]. Treatment material costs were too
small to count.
3. Direct medical costs (apart from CBT treatment)
Volumes of medical consumption were measured with a
paper and pencil questionnaire that was filled in by the
patient at base line and after treatment. Patients were
asked how many visits that they had made in the previous
six months to a GP, medical specialist, physiotherapist,
psychologist, psychiatrist and alternative medical practi-
tioner. Use of home care support (average hours per week
in the last 6 months) hospitalization (number of nights in
6 months) and use of (prescribed and not prescribed)
medication were also asked. To value patients' medical
consumption, cost prices were used as given in the Dutch
cost analyses manual [16] after recalculating them to the
2004 price level (Table 1). Costs of prescribed medication
were calculated based on the Dutch indicated market
Table 1: Cost-prices used to value the different health care volumes, measured at patient level before and after treatment.
Health care volume Cost price
General practitioner (per visit) € 20.39
Medical specialist (per visit) € 63.99
Physiotherapist (per visit) € 22.96
Psychologist (per visit) € 125.14
Psychiatrist (per visit) € 88.81
Non-physician alternative medicine practitioner (per visit) € 48.87
Home care (per hour) € 21.90
Informal home support (per hour) € 8.38
Hospitalization (per night) € 333.40BMC Health Services Research 2008, 8:175 http://www.biomedcentral.com/1472-6963/8/175
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prices per month based on 'defined daily doses'. Six per-
cent taxes and  6,51 pharmacy costs per client using med-
ication were added to this market costs. Patients were
asked to give a price indication per month of their costs
incurred in purchasing over-the-counter medication.
4. Direct non-medical costs
For each CFS patient traveling costs for attending the CFS
treatment sessions were applied. Distances from patients'
homes to the MHC's treatment location were found at
http://www.routenet.nl. This distance was multiplied by
each patient's total number of attended sessions. Again 
0.16 per kilometer was calculated.
5. Indirect non-medical costs
Patients' lost productivity costs due to absenteeism from
paid work were also measured with the paper and pencil
questionnaire. The questionnaire contained questions
about work and daily activities, based on the 'Health and
Labour Questionnaire' [17]. The number of hours of paid
work in the last two weeks was filled in. We valued the
days of absenteeism from paid work with Dutch standard
productivity costs specified for age, sex and education
level [16] and using the human capital method. Transfer
payments related to occupational disability insurances
were not included since these are neither a gain nor a cost
to society [10]. The productivity costs per two weeks were
then multiplied by 13 to provide the costs per 6 months.
Informal care measured at baseline and after treatment
with a paper and pencil questionnaire about the number
of hours per week that patients had received informal
care. This was costed at   8.38 per hour [16], the wage rate
for a cleaner. Time costs for patients attending the treat-
ment sessions were excluded.
Economic evaluation method
Perspective
Total costs of implementing CBT for CFS were analyzed
both from a societal perspective (including also non med-
ical costs such as travelling expenses and productivity
costs, regardless of who carried them) and from a health
care perspective (indicating that only medical costs were
relevant) [10]. For the societal perspective we calculated
costs per gained QALY. For the health care perspective
instead we calculated costs per recovered patient, being a
measure of health rather than a measure of general wel-
fare, which corresponds better to the more limited scope
of the health care perspective [18]
Calculation methods
Total costs were divided into costs for implementing the
new treatment (the fixed, so called 'organizing' costs), and
costs for facilitating and using the CBT for CFS treatments
(the variable, so called 'executing' costs) [19]. Fixed costs
were related to assembly- and organizing activities of the
working group, informational interventions towards GPs
and the public and training and supervising the initial
therapists. Variable costs comprised of: 1. Costs for con-
tinuing the treatment facility, comprising of repeatedly
providing training and supervision for new therapists (we
assumed that because of personnel turnover every two
years two new therapist need to be trained and super-
vised) and continuing PR activities; 2. Costs for clients
attending the treatment sessions (e.g. traveling costs); 3.
Costs for organizing and facilitating the treatments
(mainly labour costs); 4. Societal costs (including use of
healthcare services other than CBT and lost productivity
costs due to absenteeism from paid work) and 5. Costs for
performing the treatment program (time for therapist per-
forming the treatment sessions, costs for building use,
etc).
Because the time period between costs and effects was less
then 12 months, we did not apply the principle of dis-
counting. All costs were recalculated to 2004 by using the
2004 'derivative cost-of-living index figures' [20]. All cost
prices included in the analyses were valued in terms of
integral cost prices [16].
Data analysis
Missing data
in the original database an average of 0.5 cases per item
were randomly missing because some patients had failed
to answer all questions of a particular questionnaire.
These missing data were filled in with the median value
for the particular item. In the cases of missing data due to
loss of follow up the method of last observation carried
forward was used [21], indicating that intake measure-
ments were used as post treatment. Analyses were per-
formed on basis of intention to treat; patients who
attended an intake but did not start treatment and
patients who dropped out of treatment were all included
in the cost analyses.
Cost and outcome calculations
Given the non-controlled design of the present study, it
did not fulfil the criteria of a 'full economic evaluation'
[10], and hence the usually calculated incremental costs
effectiveness ratios (ICER) could not be analysed. In stead
we calculated cost outcome ratios (CORs). Cost outcome
ratios (COR) are concerned with the joint difference in
costs and outcomes before and after (implementing and)
performing a certain treatment [10]. This ratio thus indi-
cates the financial investment that is needed to gain a cer-
tain treatment effect, based on the assumption that
autonomous change regarding the patients is negligible.
The COR was calculated in two ways. First by defining
treatment effect as 'percentage of recovered patients'BMC Health Services Research 2008, 8:175 http://www.biomedcentral.com/1472-6963/8/175
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(health care perspective), and second by using quality
adjusted life-years (QALYs) as a measure for treatment
effect (societal perspective). The recovery rate was ana-
lysed by calculating the percentage of patients experienc-
ing significant clinical improvement (CSI). Patients were
defined as being CSI at post treatment if they had a relia-
ble change index > 1.96 on the CIS fatigue severity sub-
scale [22], a fatigue severity score <= 35 and a Rand-36
physical functioning score > = 65 [12]. Quality of life was
measured using utility scores of the Euroqol [14]. This
utility score, lying between 0 (health state equal to death)
and 1 (perfect health state), represents the QALY due to
some intervention.
Since the health care costs were measured over a period of
6 months, while the individual durations of treatment dif-
fered between 2.2 and 16.2 months, all medical and non-
medical costs at follow up were extrapolated to the indi-
vidually defined treatment period, before including them
in the cost outcome analyses.
Utility scores were measured two times, at intake and at
follow up. Since the difference in utility scores between
the two measurements was presumably reached gradually
instead of at once, and because the duration of treatment
differed per patient, the gained QALYs at post treatment
were calculated as: 0.5 * (utility score post treatment –
utility score intake)/12 * individual number of months of
treatment [10].
Analysis of uncertainty
Because it was presumed that, as usually, the measured
medical costs would follow a skewed distribution, a nor-
mality assumption would be problematic when estimat-
ing confidence intervals. Therefore the non-parametric
bootstrap method [23] was used to quantify the uncer-
tainty of the calculated COR. In the bootstrap method this
uncertainty is quantified by plotting cost-effectiveness
acceptability (CEA) curves by means of repeated re-sam-
pling of the costs and outcome data (the bootstrapping),
which generates a distribution of mean costs and out-
comes of two situations [24]. These distributions are then
used to calculate the probability that one of the situations
is the optimal choice, given a range of possible maximum
values (ceiling ratio) that a decision maker might be will-
ing to pay for a unit of improvement in outcome. Because
the present study did not calculate cost effectiveness, we
used the term 'COR acceptability curve' instead of 'ICER
acceptability curve'.
Scenario calculation
For both the societal and the healthcare perspective, the
COR of implementing CBT for CFS in a MHC was also cal-
culated for a period of 5 years.
Results
Descriptives
Figure 1 presents the patient flow. From the 143 patients
that entered the MHC during the observation period, 18
'no show' patients never showed up at the intake session.
Since they only caused negligible costs they were excluded
from this study. The remaining 125 patients were
included. At intake 13 patients appeared not to fulfil the
diagnostic criteria for CFS, these patients did not start
treatment. Of the 112 patients that started treatment, 28
dropped out of treatment quickly after the intake session.
Of the 84 patients that followed treatment 12 dropped
out half way or later and 72 finished treatment.
Missing data
At 8 months follow up 74 of the 84 treated patients filled
in the questionnaire and 10 patients failed to do this (7
drop out patients and 3 treatment completers). Of the 13
'non CFS' and the 28 'non starting' patients their intake
measurements were used as post treatment, since no treat-
ment effect was to be expected within less than 2 sessions.
Sample characteristics
Patients' characteristics are shown in Table 2. Of the 77
patients (62%) that had a paid job (42 fulltime and 35
part time) 54 were actually working and 23 were on sick-
ness benefit.
Treatment characteristics
The mean duration of the 84 performed treatments was
8.4 months (SD 3.3) and varied from 2.2 to 16.2 months.
Patient flow Figure 1
Patient flow.BMC Health Services Research 2008, 8:175 http://www.biomedcentral.com/1472-6963/8/175
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No relations were found between duration of treatment
and several other variables, like treatment effect, decrease
in medical consumption or lost productivity costs after
treatment. The mean number of treatment sessions was
14.5 (SD 5.6) and varied from 6 to 23 sessions.
Treatment effects
Effect based on fatigue severity: after treatment 46 of 125
patients (37%) were recovered. Effect based on Euroqol:
the mean utility score at intake was 0.57 (SD 0.27) and
post treatment 0.65 (SD 0.30) (table 3).
Costs results
Table 4 shows the total fixed and variable costs of prepar-
ing and introducing the implementation of CBT for CFS,
with a total of   90.765 and   59.300 respectively. The
costs results of performing and using CBT (table 5) reveal
that per patient a mean of   597 were spent per CBT treat-
ment.
Table 6 gives the amounts of medical care other than CBT
treatment. These results were used for calculating all
(non) medical costs (table 7). As can be seen, total medi-
cal costs decreased from   1.112 per six months before
treatment to   810 after treatment (95% CI -  784 to -
26). Total non-medical costs also decreased, from   1.249
per six months before treatment to   1.012 after treatment
(95% CI -  813 to   271).
In table 8 the figures on work and absenteeism are given,
showing that the mean number of working hours accord-
ing to contract had fallen from 16.4 per week before treat-
ment to 14.9 after treatment (95% CI -5.4 to 3.2). The
number of real worked hours however had risen from 9.3
before treatment to 11.4 hours per week after treatment
(95% CI – 2.6 to 5.5), implying that the number of lost
productivity hours and its costs decreased, from   218 per
patient per week before treatment tot   122 after treat-
ment (95% CI -  173 to -  6).
Cost outcome ratios
From the societal perspective the mean societal costs per
patient per six months were   8.030 before implementing
CBT for CFS and   6.869 after it (95% CI -  3.489 to 
1.083). The mean gained QALY per patient was 0,03.
Given the lower cost level and a higher health state of
patients, the COR-estimate indicates dominancy. The five
years scenario calculation analysis, in which the total
amount of treated patients was up-scaled to 3.33 times the
amount of patients that were treated in the implementa-
tion period of 1,5 years (also figure 2), revealed a greater
than 90% probability for a favorable COR for all accepta-
bility thresholds.
From the health care perspective it was found that mean
costs per patient per six months were   1.117 before
implementation and treatment and   2.586 after it (95%
CI   958 to   1.876). Given the recovery rate of 37% the
COR of implementing CBT for CFS was   5.320 per recov-
ered CFS patient. The COR acceptability curve (figure 3)
shows that the probability that implementing CBT for CFS
has a favorable COR is 100% when the decision maker
values a recovered CFS patient at least   6.500.
The 5 years scenario calculation (also figure 3) showed
that the 100% guarantee for an acceptable COR was
reached at the willingness to pay threshold of   4.500.
Sensitivity analysis
In sensitivity analysis applied for the societal perspective,
the costs for (informal) home care and productivity costs
were varied. As also has been found in other studies [7,8]
(informal) home care appeared to cause major costs.
Besides that questions may be raised about the accuracy of
the measured amounts of home care. It is a difficult aspect
to measure, for example the distinction between informal
care and normal household activities is not clearly
defined, both for researchers and for patients, especially if
the informal caregiver shares a household with the patient
[25]. Since patients have a tendency to overestimate their
hours of informal care, we performed a calculation reduc-
ing informal home care to 50% and leaving it out at all. In
Table 2: Patients' characteristics (N = 125)
Categorical variables (N/%)
Sex (man/women) 42 (34%)/83 (66%)
Higher education 51 (41%)
Having a paid job 77 (62%)
Married/living together/living with parents 98 (78%)
Continuos variables M (SD)
Age 38.7 (10.2)
Duration of fatigue (years) 6.3 (7.0)
Fatigue severity (Cis20) 48.3 (8.0)
Physical impairment (Rand 36) 54.0 (23.4)
Social impairment (Rand 36) 41.5 (23.7)
Psychosocial well-being (SCL-90) 165.1 (42.1)
Table 3: Mean utility scores at intake and 8 months follow up (N = 125)
Intake Follow up Δ follow up – intake 95% CI P
Mean (SD) 0.57 (0.27) 0.65 (0.30) 0.078 (0.028) 0.03 to 0.09 < 0.001BMC Health Services Research 2008, 8:175 http://www.biomedcentral.com/1472-6963/8/175
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Table 4: Costs of developing and introducing the implementation of CBT for CFS divided in fixed and variable costs.
Volume Calculated costs value per volume Costs
Personnel costs
Fixed
Therapists 647 hours € 55.50/hour € 35.909
Management 312 hours € 73.17/hour € 22.829
Others 793 hours € 35.87/hour € 28.444
Total fixed € 87.182
Variable
Therapists 460 hours € 55.50/hour € 25.530
Management 20 hours € 73.17/hour € 1.463
Supervisor 266 hours € 62.52/hour € 16.625
Others 6 hours € 35.87/hour € 215
Total variable € 43.833
TOTAL personnel costs € 131.015
Material costs
Fixed
Building use 10% of personal costs € 8.718
PR activities 2000 information letters and brochures € 1.705
Total fixed € 10.423
Variable
Building use 10% of personal costs € 4383
PR activities 2500 information letters and brochures € 1.983
Total variable € 6.366
TOTAL material costs € 16.789
Traveling costs
Fixed
Therapists 3605 km € 0.18/km € 649
Management 3328 km € 0.18/km € 599
Others 1411 km € 0.18/km € 254
Total fixed € 1.502
Variable
Supervisor 5300 km € 0.18/km € 954
Therapists 1275 km € 0.18/km € 230
Management 40 km € 0.18/km € 7
Total variable € 1.191
TOTAL traveling costs € 2.693
TOTAL fixed costs € 90.675
TOTAL variable costs € 59.300
TOTAL 'developing and introducing' costs € 149.975
All volumes were valued in terms of Dutch integral cost prices at the price level of 2004 (Oostenbrink et al., 2004).
Table 5: Mean costs per patient (in €) of using and performing CBT for CFS in mental health care (N = 125)
Mean SD Median Max
Personal costs of CBT treatment (only therapist costs) € 417 € 314 € 435 € 1349
Personal costs of CBT treatment (secretary and test assistants costs) € 28 € 7 € 34 € 34
Overhead costs and costs for building facilities € 143 € 101 € 146 € 442
Patients travelling costs (return price) € 9 € 6 € 7 € 43
TOTAL mean costs per patient of using and performing CBT for CFS € 597 € 424 € 628 € 17892BMC Health Services Research 2008, 8:175 http://www.biomedcentral.com/1472-6963/8/175
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a third calculation both informal and formal home care
were omitted from the analyses. These calculations
showed that if informal home care was omitted from the
analysis, and when both informal and formal homecare
were omitted, the probability that implementing CBT for
CFS has an acceptable COR remained above 80% for all
acceptability thresholds.
In addition, two extra analyses were done, in which pro-
ductivity costs were set to 70% and to 30% of the original
base case level. This revealed a drop in cost savings of CBT
to -  16.800 and - 18.730 respectively. It appeared that
implementing CBT for CFS remained dominant at both
the 70% and the 30% level.
Finally, to get an impression of this study's results when
compensating for spontaneous recovery, an additional
analysis was performed. This was done from the health
care perspective, presuming a spontaneous recovering rate
of 5% [2], implying a recovery rate due to treatment of
32%. It revealed that the COR would rise from   5.320 to
about   5.969 per recovered patient.
Table 6: Volumes of medical consumption (except CGT for CFS treatment) over a period of 6 months measured at patients level at 
intake and follow up (N = 125).
Intake Follow up
N Mean (SD) Median N Mean (SD) Median
Medical care
GP (number of visits) 111 3.1 (3.7) 2 93 2.0 (1.9) 2
Medical specialist (n.o. visits) 55 1.2 (1.8) 0 38 0.9 (1.5) 0
Physiotherapist (n.o. visits) 29 3.8 (9.0) 0 23 2.7 (7.4) 0
Psychologist, other than CBT for CFS 22 1.0 (3.1) 0 13 0.4 (1.4) 0
Psychiatrist (number of visits) 9 0.2 (1.2) 0 7 0.2 (1.2) 0
Home care (hours per 6 months) 21 26.9 (104.3) 0 23 22.7 (88.4) 0
Hospitalisation (nights) 13 0.4 (2.0) 0 9 0.2 (1.5) 0
Prescribed medication (yes/no) 92 77% 87 72%
Non-medical care
Informal home care (hrs per 6 months) 37 132.3 (268.3) 0 33 110.6 (182.8) 0
Altern. med. practitioner (n.o. visits) 30 1.0 (2.3) 0 21 0.8 (2.0) 0
Non prescribed medication (yes/no) 56 53% 27 35%
N = the number of patients that had been using this form of healthcare
Table 7: Mean medical and non-medical costs per 6 months measured at patient level at intake and follow up (N = 125).
Intake Follow up
Mean SD Median Mean SD Median
Medical costs
GP € 63 € 67 € 41 € 41 € 40 € 41
Medical specialist € 77 € 103 € 0 € 58 € 95 € 0
Physiotherapist € 87 € 202 € 0 € 62 € 181 € 0
Psychologist € 125 € 377 € 0 € 50 € 172 € 0
Psychiatrist € 18 € 107 € 0 € 18 € 95 € 0
Home care € 589 € 1629 € 0 € 498 € 1235 € 0
Hospitalisation € 134 € 720 € 0 € 67 € 509 € 0
Prescribed medicine € 19 € 50 € 3 € 16 € 52 € 3
Non medical costs
Alternative med. pr. € 56 € 114 € 0 € 39 € 94 € 0
Non prescr. medicine € 52 € 121 € 0 € 25 € 53 € 0
Informal homecare € 1109 € 2322 € 0 € 927 € 1573 € 0
Travelling costs € 32 € 32 € 23 € 21 € 28 € 11
Total medical costs € 1112 € 2258 € 362 € 810 € 1350 € 241
Total non-medical costs € 1249 € 2396 € 112 € 1012 € 1822 € 72BMC Health Services Research 2008, 8:175 http://www.biomedcentral.com/1472-6963/8/175
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Discussion
This study has shown that from a societal perspective the
cost outcome ratio (COR) after implementing CBT for
CFS in a MHC was dominant compared to before. From a
healthcare perspective the COR after implementation was
more costly but also more effective than before, and the
100% probability that the COR is acceptable was reached
at the willingness to pay threshold of   4.500 is positive.
Given that CBT is the only effective treatment for CFS and
has been scarcely available until now, this is relevant
information in favor of nationwide implementation.
Although some studies have already examined the cost
effectiveness of behavioral treatments for chronic fatigue
(CF) [7,8] and for CFS [9], there has been no research into
the cost effectiveness of such a treatment that also took
into account the costs of designing the implementation
interventions needed for implementing the treatment and
the costs of actually implementing the treatment in a non-
academic setting. Such a study implies a less homogenous
patient population and less control over the content of
performed treatment sessions than an academic setting
can guarantee.
Concerning age and gender, the patient population was
fully representative of the CFS population. Compared to
other trials in the area of CFS, the baseline fatigue severity
was a little lower and relatively many patients had a paid
job [26,27]. These differences could be explained by the
fact that the treatment facility at the mental health care
institution was more easily accessible. Patients may be rec-
ognized as CFS by their GP and referred to CBT in an ear-
lier phase than patients referred (mostly by a medical
specialist) to a specialized hospital setting.
As was also found in earlier cost effectiveness studies, [8,9]
an overall lower use of health care facilities was measured
after CBT for CFS than before it. This may be explained by
the fact that during treatment with CBT patients are
instructed not to use other treatments or medication and
by the fact that when starting treatment all patients were
diagnosed as CFS. Looking for a diagnosis and a lack of
affective treatment are the main reasons for CFS patients'
high use of health care facilities [28]. Concerning work
productivity, fewer patients had a paid job after treatment
than before, but the mean hours of paid work per week
had increased after treatment. Given the short time hori-
zon (8 months) the full influence of CBT for CFS on work
productivity might be revealed to be larger and the impact
on cost-effectiveness more pronounced.
In this study we used a conservative method, last observa-
tion carried forward, in cases of missing data. This impu-
tation method might have influenced the results in a
conservative, negative direction. However the proportion
Table 8: Patient volumes of work and lost productivity costs per week, measured at patient level before and after treatment (N = 
125).
Intake Follow up
Mean SD Median Max Mean SD Median Max
Number of contract hours 16.2 16.3 10 40 14.9 16.2 7 40
Number of worked hours 9.4 13.5 0 45 11.4 14.7 0 46
Absenteeism in hours 7.4 12.3 0 40 4.1 8.8 0 40
Lost productivity costs € 218 € 392 € 0 € 1544 € 122 € 292 € 0 € 1544
Acceptability curve showing the probability that implement- ing CBT for CFS has a favorable cost outcome ratio over a  range of willingness to pay regarding societal costs per QALY Figure 2
Acceptability curve showing the probability that 
implementing CBT for CFS has a favorable cost out-
come ratio over a range of willingness to pay regard-
ing societal costs per QALY. Societal willingness to pay 
for a CFS patient's gained QALY.
Acceptability curve showing the probability that implement- ing CBT for CFS has a favorable cost outcome ratio over a  range of willingness to pay regarding health care costs per  recovered patient Figure 3
Acceptability curve showing the probability that 
implementing CBT for CFS has a favorable cost out-
come ratio over a range of willingness to pay regard-
ing health care costs per recovered patient. 
Willingness to pay for recovering a CFS patient.BMC Health Services Research 2008, 8:175 http://www.biomedcentral.com/1472-6963/8/175
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of missing data was in our opinion rather small (< 12%)
thus the chance that significantly different results were
obtained is small.
A serious limitation of this study is it's non-controlled
before and after design, which implies that incremental
cost effectiveness compared to a natural course control
group, or compared to a guided support group controlling
for any placebo effect, could not be analysed. However,
the incremental cost effectiveness ratio (ICER) of CBT for
CFS compared to usual care was recently reported by Sev-
erens et al. [9]. The focus and contribution of the present
study was primarily to investigate costs and consequences
of implementing this evidence based treatment in a clini-
cal practice setting. This is a relevant issue in bridging the
gap between science and research, since proven (cost)
effectiveness under laboratory conditions of RCTs does
not guarantee the same in the practice field of health care.
Both smaller treatment effects due to the less controlled
situation and accompanying costs of including costs for
implementing the treatment might change the cost-out-
come ratio.
Another weak point in this study is the variable follow up
time. Although the mean time period between intake and
post treatment was 8.4 months, and analyses were done
using this time horizon for all patients, the real time inter-
val varied considerable. The problem hereby is that in fact
we do not know what this implies for the results that were
found.
A strong point though is the fact that, besides the usual
included medical-, productivity-, and patient related costs
also protocol driven- and implementation related costs
were included [29], giving a more complete and more rel-
evant view on the cost and outcomes of providing nation-
wide CBT for CFS.
Conclusion
To conclude, the results of this study suggest that imple-
menting cognitive behavioral therapy for chronic fatigue
syndrome in a mental health center is feasible and advis-
able. This strategy appeared to be dominant (resulting in
lower costs and higher health states) compared to the
starting situation from a societal perspective. From a
health care perspective the implementation also implied
better health states, but also higher costs, and the proba-
bility of a positive cost outcome ratio depended on how
much value is placed on a recovered CFS patient. The out-
comes of this study might facilitate the decision for health
care providers whether or not to adopt CBT for CFS in
their institution.
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